Immunitybio Stock Today
| IBRX Stock | USD 6.45 0.89 12.13% |
PerformanceSolid
| Odds Of DistressHigh
|
Immunitybio is trading at 6.45 as of the 24th of January 2026; that is 12.13 percent decrease since the beginning of the trading day. The stock's open price was 7.34. Immunitybio has more than 66 % chance of experiencing financial distress in the next few years of operation. However, it had a very solid returns during the last 90 days. The performance scores are derived for the period starting the 26th of October 2025 and ending today, the 24th of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of July 2015 | Category Healthcare | Classification Health Care |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The company was founded in 2014 and is based in San Diego, California. The company has 984.97 M outstanding shares of which 120.64 M shares are currently shorted by private and institutional investors with about 8.61 trading days to cover. More on Immunitybio
Moving against Immunitybio Stock
Immunitybio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Richard Adcock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImmunitybio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunitybio's financial leverage. It provides some insight into what part of Immunitybio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunitybio (IBRX) is traded on NASDAQ Exchange in USA and employs 673 people. Immunitybio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.35 B. Immunitybio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 984.97 M outstanding shares of which 120.64 M shares are currently shorted by private and institutional investors with about 8.61 trading days to cover.
Immunitybio currently holds about 82.94 M in cash with (391.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.21.
Check Immunitybio Probability Of Bankruptcy
Ownership AllocationImmunitybio has a total of 984.97 Million outstanding shares. Immunitybio retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 66.41 (percent) of Immunitybio outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Immunitybio Ownership Details
Immunitybio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Citigroup Inc | 2025-06-30 | 2.5 M | |
| Tang Capital Management Llc | 2025-06-30 | 2.3 M | |
| Susquehanna International Group, Llp | 2025-06-30 | 1.9 M | |
| Northern Trust Corp | 2025-06-30 | 1.8 M | |
| Charles Schwab Investment Management Inc | 2025-06-30 | 1.8 M | |
| Royal Bank Of Canada | 2025-06-30 | 1.2 M | |
| Ubs Group Ag | 2025-06-30 | 1.2 M | |
| Jpmorgan Chase & Co | 2025-06-30 | 1.1 M | |
| Bsc Private Wealth Management, Llc | 2025-06-30 | 846.4 K | |
| Vanguard Group Inc | 2025-06-30 | 21.8 M | |
| Blackrock Inc | 2025-06-30 | 17.8 M |
Immunitybio Historical Income Statement
Immunitybio Stock Against Markets
Immunitybio Corporate Management
| Jason JD | General Secretary | Profile | |
| Sandeep MD | Chief Officer | Profile | |
| Helen Luu | Chief Officer | Profile | |
| Leonard MD | Chief Officer | Profile | |
| Jason Liljestrom | General Secretary | Profile | |
| Bruce MD | Senior Affairs | Profile |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.